You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Cigna Group reported adjusted EPS of $7.98 for third quarter 2026 and raised full-year adjusted EPS outlook to at least $30.60. It expects at least 10% adjusted EPS growth in 2027 and at least $45 in 2030.
Donna F. Zarcone will retire from The Cigna Group’s Board effective December 31, 2026; her retirement is not due to any disagreement with the Company.
The Cigna Group introduced “Lead to One,” announced a $3 billion multi-year modernization and productivity program, reaffirmed 2026 adjusted EPS of at least $30.45, and set a 10-14% Adjusted EPS CAGR target.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Cigna reported Q2 2026 adjusted EPS of $7.78 on $71.7B in revenues and raised full-year 2026 adjusted EPS guidance to at least $30.45, while Cigna Healthcare pre-tax adjusted earnings grew 17% but Pharmacy Benefit Services pre-tax adjusted earnings fell 27% year-over-year amid GLP-1 moderation and a higher 84.5% MCR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted revenues | $73.79B | FY2026 Q3 | +6.1% |
|
|
|||
| Consolidated pre-tax adjusted income from operations | $2.65B | FY2026 Q3 | +2.8% |
|
|
|||
| Adjusted Income from Operations non-GAAP | $2.05B | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Shareholders' Net Income 1.66B
-55M Net Investment (Gains)
+296M Amortization of Acquired Intangible Assets
+153M Special Items
= Adjusted Income from Operations 2.05B
|
|||
| Adjusted Income from Operations, per share non-GAAP | $7.78 | Three Months Ended June 30, 2026 | — |
| Adjusted revenues by segment - Other Operations non-GAAP | $131M | Three Months Ended June 30, 2026 filing | — |
| Behavioral Care | 27.62M | As of June 30, 2026 | — |
| Cigna Healthcare Adjusted Income from Operations, Pre-Tax non-GAAP | $1.28B | Three Months Ended June 30, 2026 | — |
| Cigna Healthcare Adjusted Revenues non-GAAP | $11.73B | Three Months Ended June 30, 2026 | — |
| Cigna Healthcare Margin, Pre-Tax non-GAAP | 10.9% | Three Months Ended June 30, 2026 | — |
| Cigna Healthcare Medical Care Ratio | 84.5% | Three Months Ended June 30, 2026 | — |
| Corporate and Other Operations Adjusted (Loss) from Operations, Pre-Tax non-GAAP | -$389M | Three Months Ended June 30, 2026 | — |
| Dental | 18.49M | As of June 30, 2026 | — |
| Evernorth Health Services Adjusted Income from Operations, Pre-Tax non-GAAP | $1.66B | Three Months Ended June 30, 2026 | — |
| Evernorth Health Services Adjusted Revenues non-GAAP | $61.47B | Three Months Ended June 30, 2026 | — |
| Evernorth Health Services Margin, Pre-Tax non-GAAP | 2.7% | Three Months Ended June 30, 2026 | — |
| Pharmacy claim volume non-GAAP | 537M | Three Months Ended June 30, 2026 filing | — |
| Pre-tax adjusted income from operations by segment - Other Operations non-GAAP | $21M | Three Months Ended June 30, 2026 filing | — |
| Total Customer Relationships | 182.77M | As of June 30, 2026 | — |
| Total Medical Customers | 18.41M | As of June 30, 2026 | — |
| Total Pharmacy Customers | 118.24M | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CI
this stock
Cigna Group
|
$80.70B | +9.5% | +11.2% | 13.5 | 2.6% |
|
UNH
Unitedhealth Group Inc
|
$354.57B | +19.9% | +11.8% | 22.6 | 1.6% |
|
CVS
CVS HEALTH Corp
|
$102.31B | +2.5% | +7.8% | 9.3 | 1.3% |
|
ELV
Elevance Health, Inc.
|
$93.81B | +23.2% | +12.5% | 18.4 | 2.4% |
|
HUM
Humana Inc
|
$50.12B | +60.8% | +10.1% | 39.4 | 3.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CI | +1.0% | +7.3% | +5.7% | +1.1% | +9.5% |
| SPY | -4.7% | -5.3% | -0.8% | -3.0% | +7.5% |
| vs SPY | +5.8% | +12.6% | +6.5% | +4.1% | +2.1% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
